CIK 0001678660 · Non-accelerated filer<br>Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811384762
- Phone
- (302) 467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 62 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-16 | Babler Martin Director | Grant or award · Director Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2023-05-25 | Vaddi Krishna CEO | Purchase | +900 | $5.31 | $5K | 1,067,275 |
| 2023-05-24 | Vaddi Krishna CEO | Purchase | +1,000 | $5.01 | $5K | 1,066,375 |
| 2023-05-24 | Lim Bryant David Chief Legal Officer, Corp Sec. | Purchase | +2,400 | $5.39 | $13K | 2,400 |
| 2023-05-23 | Chardonnet Laurent Chief Financial Officer | Purchase | +5,000 | $5.50 | $28K | 42,165 |
| 2023-05-23 | Vaddi Krishna CEO | Purchase | +11,856 | $5.63 | $67K | 1,065,375 |
| 2023-05-22 | BAKER BROS. ADVISORS LP Director | Grant or award · Prelude Non-Voting Common Stock | +121,178 | $5.75 | $697K | 630,658 |
| 2023-05-22 | BAKER BROS. ADVISORS LP Director | Grant or award · Prelude Non-Voting Common Stock | +1,327,044 | $5.75 | $7.6M | 6,539,415 |
| 2023-05-22 | BAKER BROS. ADVISORS LP Director | Grant or award · Warrants to purchase Common Stock | +970,220 | $5.75 | $5.6M | 970,220 |
| 2023-05-22 | BAKER BROS. ADVISORS LP Director | Grant or award · Warrants to purchase Common Stock | +10,625,036 | $5.75 | $61.1M | 10,625,036 |
| 2023-05-22 | ORBIMED ADVISORS LLC Director | Purchase | +869,565 | $5.75 | $5.0M | 10,119,756 |
| 2023-05-22 | Bonita David P Director | Purchase | +869,565 | $5.75 | $5.0M | 10,119,756 |
| 2023-04-06 | Huang Jane President, CMO | Sale | −13,280 | $6.12 | $81K | 24,220 |
| 2023-04-04 | Huang Jane President, CMO | Option exercise | +37,500 | 37,500 | ||
| 2023-04-04 | Huang Jane President, CMO | Option exercise · Restricted Stock Unit | −37,500 | 112,500 | ||
| 2023-03-01 | Lim Bryant David Chief Legal Officer, Corp Sec. | Grant or award · Employee Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2023-02-07 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2023-02-07 | Combs Andrew EVP, Head of Chemistry | Grant or award · Employee Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2023-02-07 | Chardonnet Laurent Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2023-02-07 | Huang Jane President, CMO | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 |
Page 6 of 8 · 141 trades